Inspire Medical Q2 revenue up 11%

Inspire Medical Systems

04/08/2025 21:13

Overview

Inspire Medical Q2 2025 revenue rises 11%, beating analyst expectations, per LSEG data

Company reports net loss of $3.6 mln

Launch of Inspire V system slower than expected, affecting financial outlook

Outlook

Inspire lowers 2025 revenue guidance to $900 mln-$910 mln

Company maintains 2025 gross margin guidance of 84%-86%

Inspire expects 2025 diluted EPS of $0.40-$0.50

Company cites slower U.S. launch of Inspire V for guidance cut

Result Drivers

INSPIRE V LAUNCH - Full launch of Inspire V system in U.S. is a key milestone, but slower than expected, impacting financial results

INVENTORY CHARGE - $2.1 mln charge due to excess components inventory related to Inspire IV

OPERATING EXPENSES - Increased by 15% due to U.S. sales expansion, marketing, and legal costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$217.10 mln
$214.30 mln (16 Analysts)
Q2 EPS
-$0.12
Q2 Net Income
-$3.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Inspire Medical Systems Inc is $210.00, about 40% above its August 1 closing price of $126.10

The stock recently traded at 45 times the next 12-month earnings vs. a P/E of 63 three months ago

Press Release: ID:nGNX1ZLwst

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)